Re: Two Centres’ Experience With Lung Cancer Resection in Patients With Advanced Non-Small-Cell Lung Cancer Following Treatment With Immune Checkpoint Inhibitors: Safety and Clinical outcomes

This invited commentary offers insights into a manuscript that provides a deeper understanding of the perioperative outcomes of patients with stage II/IV non-small-cell lung cancer (NSCLC) with tumour resection after neoadjuvant immunotherapy, alone or as part of multimodal treatment.